The present invention provides an epitope peptide that is derived from KOC1 and that has cytotoxic T cell induction potency. The present invention also provides a polynucleotide that codes for the peptide, antigen-presenting cells that present the peptide and cytotoxic T cells that target the peptide, and a method for inducing the antigen-presenting cells or the cytotoxic T cells. The present invention also provides a composition and a pharmaceutical composition that include the peptide, etc. as active components. The present invention also provides a method for the treatment and/or prevention of cancer and/or the prevention of the postoperative recurrence of cancer, the method using the peptide, the polynucleotide, the antigen-presenting cells, and the cytotoxic T cells of the present invention or using the pharmaceutical composition of the present invention. The present invention also provides a method for inducing an immune response to cancer.本發明提供具有細胞傷害性T細胞誘導能力之來自KOC1的抗原決定位胜肽。本發明並提供編碼為該胜肽之多核苷酸、呈現該胜肽之抗原呈現細胞及誘導以該胜肽為標靶之細胞傷害性T細胞、及該抗原呈現細胞或該CTL之方法。本發明更包含以該等作為有效成分之組合物及藥學組合物。本發明更提供使用本發明之胜肽、多核苷酸、抗原呈現細胞、細胞傷害性T細胞、或本發明之藥學組合物來治療及/或預防癌,及/或預發術後之癌再發之方法。又,提供誘導對於癌之免疫應答之方法。
